NLS Pharmaceutics Secures Patent for Dual Orexin Receptor Agonists
The new patent application from Aexon Labs, licensed to NLS Pharmaceutics, covers dual orexin receptor agonists designed to treat narcolepsy.
Source: sleepreviewmag.com
Eric Konofal News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Eric Konofal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Eric Konofal Today - Breaking & Trending Today
NLS Pharmaceutics AG: NLS Pharmaceutics Reports Positive Results from Study KO-874 on Mazindol's Neuroprotective Effects in Narcoleptic-like Rat Model
ZÜRICH, SWITZERLAND / ACCESSWIRE / May 28, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies
Source: finanznachrichten.de
NLS Pharmaceutics : UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS - Form 6-K -December 06, 2023 at 04:49 pm EST
UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Page ...
Source: marketscreener.com
NLS Pharmaceutics Acquires Rights to Orexin Agonist Platform
NLS Pharmaceutics entered into an exclusive option agreement with Aexon Labs to develop its dual orexin receptor agonists platform.
Source: sleepreviewmag.com
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and ...
NLS Pharmaceutics Announces Exclusive Option Agreement to Develop and ...
Source: pr-inside.com